• 구독신청
  • My스크랩
  • 지면신문
FNTIMES 대한민국 최고 금융 경제지
ad

Chairman Cho Dong-gil, Who Inherited the Family Business, Outperforms His Older Brother

신혜주 기자

hjs0509@fntimes.com

기사입력 : 2025-05-29 08:29

◇ Last year, Cho Dong-gil received KRW 5,879 million, while Cho Dong-hyuk received KRW 2,167 million

(From left) Cho Dong-gil, Chairman of Hansol Group, and Cho Dong-hyuk, Chairman of Hansol Chemical. /Photo courtesy of Hansol Group

(From left) Cho Dong-gil, Chairman of Hansol Group, and Cho Dong-hyuk, Chairman of Hansol Chemical. /Photo courtesy of Hansol Group

[Korea Financial Times, Shin Haeju] Chairman Cho Dong-gil of Hansol Group received a total remuneration of KRW 5,879 million last year. Chairman Cho Dong-hyuk of Hansol Chemical received KRW 2,167 million.

Both are sons of the late Lee In-hee, the former advisor who founded Hansol Group and the eldest daughter of the late Lee Byung-chul, the founder of Samsung. Cho Dong-hyuk is the eldest son, and Cho Dong-gil is the third son. The second son, Vice Chairman Cho Dong-man, left Hansol Group in the early 2000s after splitting off his affiliated companies.

According to the Financial Supervisory Service’s electronic disclosure system, Chairman Cho Dong-gil last year received KRW 1,002 million from Hansol Holdings, KRW 3,950 million from Hansol Paper, and KRW 927 million from Hansol Technics.

Although Chairman Cho Dong-hyuk is a non-registered director at Hansol Chemical, he received KRW 2,167 million from the company last year.

Hansol Group was established in 1991 when the late advisor Lee In-hee separated Jeonju Paper from Samsung. At that time, her three sons, who had been working at Samsung affiliates, gathered at Hansol, and from 1997, all three brothers served as vice chairmen and participated in management.

Eldest son Cho Dong-hyuk entered the finance industry based on his experience at Samsung C&T and Kangbuk Samsung Hospital. Second son, former Vice Chairman Cho Dong-man, led the information technology (IT) division and spearheaded the personal communication service (PCS) business.

The third son, Cho Dong-gil, was the first among the brothers to join Hansol. After working at Samsung C&T and J.P. Morgan, he began his management training as head of planning at Jeonju Paper in 1987.

Initially, the three brothers jointly managed the group, but at the end of 2001, Hansol Group shifted to a single-leader system under Chairman Cho Dong-gil. After the previous financial crisis, the finance and IT sectors faced difficulties, causing the eldest and second sons to move away from succession.

An industry insider commented, “The eldest and second sons chose finance and IT, which seemed more promising than the paper business, but ultimately did not achieve their goals. As a result, the youngest, Chairman Cho Dong-gil, naturally inherited the family business and now leads Hansol Group.”

Shin Haeju (hjs0509@fntimes.com)

데일리 금융경제뉴스 FNTIMES - 저작권법에 의거 상업적 목적의 무단 전재, 복사, 배포 금지
Copyright ⓒ 한국금융신문 & FNTIMES.com

가장 핫한 경제 소식! 한국금융신문의 ‘추천뉴스’를 받아보세요~

KFT Topic 다른 기사

1 Kia's Three Growth Engines Fuel Its Historic Charge Toward No. 1 The long-standing formula of South Korea's auto market — Hyundai Motor No. 1, Kia No. 2 — is showing cracks. Kia has narrowed the sales gap with Hyundai Motor to within striking distance, and forecasts that it will claim the top spot in domestic sales for the first time in its history this year are increasingly becoming reality.Kia's sales momentum is attributed to solid performance in its core SUV lineup, combined with the successful rollout of new lineups such as mass-market electric vehicle (EV) models and purpose-built vehicles (PBVs).According to Kia's disclosure on the 28th, the compan 2 SK Biopharmaceuticals Doubles Down: $795M Bet on Second Blockbuster Epilepsy Drug "SK Biopharmaceuticals has now entered a different league, one in which we compete directly with global big pharma companies in the United States and Europe, not just in Korea."President Lee Dong-hoon of SK Biopharmaceuticals made this declaration at a press conference held on the afternoon of the 26th at the Westin Josun Hotel in Jung-gu, Seoul, where he abruptly unveiled the company's license-in (L/I) agreement to acquire opakalim, an epilepsy drug candidate from Ireland-based Biohaven.Through the deal, SK Biopharmaceuticals aims to reduce its reliance on a single product — cenobamate — an 3 Naver Bets on AI Infrastructure While Kakao Bets on Agentic AI South Korea's two leading platform companies, Naver and Kakao, are maintaining similar levels of research and development (R&D) investment relative to revenue in the first half of this year, but they are pursuing markedly different strategies to secure AI competitiveness.Naver is focused on expanding AI infrastructure, while Kakao — taking its spinoff as an opportunity — is concentrating on strengthening agentic AI services.According to the Financial Supervisory Service's electronic disclosure system on the 24th, Naver's and Kakao's R&D spending in the first half of 2026 came to KRW
ad
ad
ad

한국금융 포럼 사이버관

더보기

FT카드뉴스

더보기
[그래픽 뉴스] ISA 대개편! 나에게 유리한 계좌는?
[그래픽 뉴스] 미국 증시 새로운 키워드 'MANGOS'
환전·로또·육아휴직까지 하반기부터 달라지는 제도 TOP11
[그래픽 뉴스] 은퇴후 30년 부모님 세대의 생존전략
[그래픽 뉴스] 퇴근 후 주차했는데 수익 발생? V2G의 정체

FT도서

더보기